Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an initially local reaction leading to a systemic inflammatory......
Rezvilutamide ( ((R))) is an oral, second-generation androgen receptor antagonist being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatme......
Rezafungin (Rezzayo (TM)), an intravenous once-weekly echinocandin that inhibits 1,3-beta-d-glucan synthase, is being developed by Cidara Therapeutics......
Remdesivir (Veklury(& REG;)), a nucleotide analogue prodrug with broad-spectrum antiviral activity, is approved for the treatment of coronavirus d......
Lecanemab (lecanemab-irmb; LEQEMBI (TM)) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-beta p......
Background Berberine is a nutraceutical that can improve lipid metabolism. Berberine may also affect sex hormones and exert sex-specific lipid-modifyi......
Irritable bowel syndrome (IBS) is a disorder of a gut-brain interaction characterised by abdominal pain and a change in stool form or frequency. Curre......
Ovarian cancer is the leading cause of gynecological cancer death. Improved understanding of the biologic pathways and introduction of poly (ADP-ribos......
Motixafortide (APHEXDATM) is a selective C-X-C motif chemokine receptor 4 (CXCR4) inhibitor being developed by BioLineRx under licence from Biokine Th......
Tremelimumab (tremelimumab-actl; IMJUDO (R)), a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blocking antibody, is being developed by AstraZen......
Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin((R))) is a non-replicating adenoviral vector-based gene therapy developed by Ferr......
BackgroundMany clinical trials have reported that low-dose aspirin decreases the risk of pre-eclampsia in women with prior pre-eclampsia. However, its......
Tofersen (Qalsody((TM))) is an antisense oligonucleotide being developed by Biogen for the treatment of amyotrophic lateral sclerosis (ALS). On 25 Apr......
Efbemalenograstim alfa (Ryzneuta(& REG;)) is a subcutaneously administered recombinant fusion protein that is being developed by Evive Biotech for......
